Skip to content
VietVance

Site search

Listed Companies

OPC Director and Related Parties Register to Sell Nearly 16% Stake

Vietnamese pharmaceutical company OPC says four insiders and related parties have registered to sell nearly 12 million shares, representing about 16% of its charter capital. One director plans to sell his entire holding. Revenue and after-tax profit both fell year on year in the third quarter of 2026.

VietVance

1 min read

Vietnamese pharmaceutical company CTCP Dược phẩm OPC (stock code: OPC) disclosed that four insiders and related parties have registered to sell a combined nearly 12 million shares, representing about 16% of its charter capital. The transactions are still at the registration stage.

Director Trịnh Xuân Vương plans to sell his entire holding of more than 10.61 million shares, representing 14.16% of the company's charter capital. The sale is scheduled for November 20 to December 19 through negotiated transactions and order matching. He served as the company's chairman for about 10 years before becoming a director in October 2021. Based on the November 19 closing price of VND 18,700 per share, the shares registered for sale are worth about VND 198 billion.

OPC's share price performance since the start of 2025.(VietVance)

During the same period, Trịnh Xuân Vương's daughter-in-law, Đỗ Thụy Như Hà, plans to sell her entire holding of more than 1.24 million shares, representing 1.66% of charter capital; his son, Trịnh Việt Tuấn, plans to sell 69,905 shares, representing 0.09%. Company secretary Nguyễn Thị Hồng plans to sell her entire holding of 68,759 shares, or about 0.092% of charter capital, between November 23 and December 22.

OPC's predecessor was established in 1977. The company produces and sells pharmaceuticals, including herbal medicines, and currently has charter capital of VND 749 billion. In the third quarter of 2026, net revenue was about VND 258 billion, down 5.5% year on year, while after-tax profit was VND 29 billion, down 10%. In the first nine months, net revenue reached about VND 736 billion, up 2% year on year, while after-tax profit was about VND 78 billion, down slightly. The company said its third-quarter results were affected by new tax rules for household businesses that weighed on its over-the-counter sales channel, tighter regulation of prescription drugs and competitive pressure in the market.

Source: VietVance

Related